GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Zejula’s once-daily treatment regimen will be attractive to doctors and patients, compared with Lynparza, which is taken as eight 50mg capsules per day. However Tesaro is a newcomer to Europe ...

A cohort with germline BRCA-mutated ER-positive, HER2-negative breast cancer responded to Zejula and Jemperli in the TBCRC-056 trial. Pathological complete response rate was 16.7%, with 44.4% ...

Dec 20 (Reuters) - GSK (GSK.L), opens new tab said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in ...

GSK plc has announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula (niraparib) and Jemperli (dostarlimab) in first line advanced ovarian cancer. The trial met its ...

posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza in ovarian cancer, GSK delivered a similar message for its Jemperli-Zejula cocktail.

GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial. The British drug maker said ...